CEO Peter Foley said that the company also intends to invest more in its consumer testing platform and will build out its data science team to improve the results it delivers to patients.
Makers of genetic health risk tests will only need one FDA review before commercializing tests, with some exceptions.
A Color Genomics collaborator reported that nearly half of first-degree relatives who were invited for reduced-cost testing in cancer-related genes opted to participate.
A number of experts have questioned the clinical validity underlying Interleukin's tests and hope Orig3n will not revive them.
The company has contracted with a urologist, who will review customers' requests for tests, and prescribe the firm's epigenetics-based male fertility analysis.
Xifin customers will be able to access lab services in support of consumer-initiated testing and employer-based screening programs, as part of the deal.
The company, which has offices in Italy and New York, outsources the analysis to partner laboratories and offers genetic counseling as an option.
The re-emergence of direct-to-consumer genetic health risk tests has healthcare providers worried once again about their impact and utility.
The firm said that the service provides analysis of fitness and health by measuring the body's internal markers at a time of increasing uptake for external health tracking devices.
Genomed, based in Warsaw, offers sequencing-based diagnostic and research services and brought BGI's noninvasive prenatal NIFTY test in house last year.